APL-3007, pegcetacoplan (APL-2)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug Information

Target Indication

Geographic Atrophy Secondary to Age-related Macular Degeneration

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

APLS

Apellis Pharmaceuticals, Inc.

Related Pipeline

Paroxysmal Nocturnal Hemoglobinuria

Geographic Atrophy Secondary to Age-related Macular Degeneration

Paroxysmal Nocturnal Hemoglobinuria

Geographic Atrophy Secondary to Age-related Macular Degeneration

C3G